Veritone, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Veritone, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $23.19M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $92.64M | Apr 1, 2025 |
| FY2024 | Dec 31, 2023 | $99.99M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $149.73M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $115.31M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $57.71M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $49.65M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $27.05M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $14.41M | Mar 18, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.19M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $92.64M | Apr 15, 2026 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $14.41M | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $8.91M | Mar 9, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $32.36M | Mar 11, 2020 |
| FY2019 | Dec 31, 2018 | $20.57M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $13.34M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $7.33M | Mar 9, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($111.73M) | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | ($26.49M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($37.38M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($58.63M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($25.56M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($64.67M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($47.88M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($62.08M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($61.10M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($59.60M) | Mar 18, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.25M) | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | ($19.01M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($88.21M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($99.57M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($38.00M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($61.37M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($47.67M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($64.07M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($61.99M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($46.76M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.71M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $26.82M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $40.59M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $43.59M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $25.08M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $14.38M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $22.78M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $22.10M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $13.97M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $7.90M | Mar 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($53.21M) | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | ($25.28M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($24.72M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($76.42M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $3.74M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.23M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.43M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($30.43M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($41.77M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($31.91M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.10M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.73M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $4.77M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.02M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $175.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $293.0K | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $3.72M | Mar 11, 2020 |
| FY2017 | Dec 31, 2017 | $664.0K | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $37.0K | Mar 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.28M | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | $188.07M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $198.06M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $378.86M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $424.75M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $518.35M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $177.65M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $108.53M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $117.75M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $88.56M | Mar 18, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.16M | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | $184.59M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $184.61M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $340.71M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $344.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $431.85M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $89.44M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $61.12M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $57.47M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $27.26M | Mar 18, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.12M | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | $3.48M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $13.45M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $38.15M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $79.85M | Apr 1, 2025 |
| FY2023 | Dec 31, 2021 | $86.50M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $88.21M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $47.41M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $60.28M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $61.30M | Mar 11, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.26M | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | $54.37M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $53.11M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $53.53M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $46.50M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $42.03M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $6.90M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $6.90M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $5.51M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $139.0K | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($579.01M) | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | ($513.65M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($467.28M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($429.90M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($371.27M) | Apr 1, 2024 |
| FY2022 | Jan 1, 2022 | ($345.71M) | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | ($345.04M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($280.37M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($232.49M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($170.41M) | Mar 11, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.43M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $16.91M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $46.61M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $184.42M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $254.72M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $114.82M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $44.07M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $37.54M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $29.55M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $12.08M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $41.18M | Apr 1, 2025 |
| FY2023 | Dec 31, 2023 | $77.50M | Apr 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 15, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92.63M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 40.22M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 37.19M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 36.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 34.97M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 31.80M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 25.67M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | 19.34M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 16.16M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 2.62M | Mar 9, 2018 |